scholarly journals Predictive assessment in pharmacogenetics of XRCC1 gene on clinical outcomes of advanced lung cancer patients treated with platinum-based chemotherapy

2015 ◽  
Vol 5 (1) ◽  
Author(s):  
Zhengrong Yuan ◽  
Jiao Li ◽  
Ruiqi Hu ◽  
Yang Jiao ◽  
Yingying Han ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Patients ◽  
Clinical Outcomes ◽  
Advanced Lung Cancer ◽  
Xrcc1 Gene ◽  
Lung Cancer Patients ◽  
Platinum Based Chemotherapy ◽  
Predictive Assessment

Predicting toxicity in advanced lung cancer patients treated with platinum-based chemotherapy

2013 ◽  
Vol 2 (4) ◽  
pp. 281-293
Author(s):  
Georgios Ioannidis ◽  
John Souglakos ◽  
Vassilis Georgoulias
Keyword(s):  
Lung Cancer ◽  
Cancer Patients ◽  
Advanced Lung Cancer ◽  
Lung Cancer Patients ◽  
Platinum Based Chemotherapy

scholarly journals Deep Learning Analysis of CT Images Reveals High-Grade Pathological Features to Predict Survival in Lung Adenocarcinoma

Cancers ◽  
2021 ◽  
Vol 13 (16) ◽  
pp. 4077
Author(s):  
Yeonu Choi ◽  
Jaehong Aum ◽  
Se-Hoon Lee ◽  
Hong-Kwan Kim ◽  
Jhingook Kim ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Deep Learning ◽  
Cancer Patients ◽  
Clinical Outcomes ◽  
High Probability ◽  
Advanced Lung Cancer ◽  
High Grade ◽  
Lung Cancer Patients ◽  
Risk Of Death ◽  
3D Network

We aimed to develop a deep learning (DL) model for predicting high-grade patterns in lung adenocarcinomas (ADC) and to assess the prognostic performance of model in advanced lung cancer patients who underwent neoadjuvant or definitive concurrent chemoradiation therapy (CCRT). We included 275 patients with 290 early lung ADCs from an ongoing prospective clinical trial in the training dataset, which we split into internal–training and internal–validation datasets. We constructed a diagnostic DL model of high-grade patterns of lung ADC considering both morphologic view of the tumor and context view of the area surrounding the tumor (MC3DN; morphologic-view context-view 3D network). Validation was performed on an independent dataset of 417 patients with advanced non-small cell lung cancer who underwent neoadjuvant or definitive CCRT. The area under the curve value of the DL model was 0.8 for the prediction of high-grade histologic patterns such as micropapillary and solid patterns (MPSol). When our model was applied to the validation set, a high probability of MPSol was associated with worse overall survival (probability of MPSol >0.5 vs. <0.5; 5-year OS rate 56.1% vs. 70.7%), indicating that our model could predict the clinical outcomes of advanced lung cancer patients. The subgroup with a high probability of MPSol estimated by the DL model showed a 1.76-fold higher risk of death (HR 1.76, 95% CI 1.16–2.68). Our DL model can be useful in estimating high-grade histologic patterns in lung ADCs and predicting clinical outcomes of patients with advanced lung cancer who underwent neoadjuvant or definitive CCRT.

Optimum immunotherapy method according to PD-L1 expression in advanced lung cancer: a network meta-analysis

2021 ◽  
Author(s):  
Lecai Xiong ◽  
Yi Cai ◽  
Xiao Zhou ◽  
Peng Dai ◽  
Yanhong Wei ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Patients ◽  
Immune Checkpoint ◽  
Immune Checkpoint Inhibitors ◽  
Checkpoint Inhibitors ◽  
Meta Analysis ◽  
Survival Rates ◽  
Advanced Lung Cancer ◽  
Lung Cancer Patients ◽  
Platinum Based Chemotherapy

Aim: To compare the survival of advanced lung cancer patients treated with immune checkpoint inhibitors in different PD-L1 expression. Methods: We performed a network meta-analysis based on 25 trials involving 12,224 patients with different PD-L1 expression levels. Results: The results showed platinum-based chemotherapy plus pembrolizumab or nivolumab and ipilimumab was associated with the best survival rates for patients with <1% PD-L1 expression, while only platinum-based chemotherapy plus pembrolizumab produced better survival than chemotherapy in patients with 1–49% PD-L1 expression. As for patients with ≥50% PD-L1 expression, platinum-based chemotherapy plus pembrolizumab/atezolizumab and pembrolizumab/cemiplimab monotherapy were associated with better survival than chemotherapy. Conclusion: These results provide reference for selecting the optimum immunotherapy method based on the expression of PD-L1 in patients with advanced lung cancer.

Sign in / Sign up

Export Citation Format

Share Document